Insulin-like Growth Factor Binding Protein-2 (IGFBP-2) is a Marker for the Metabolic Syndrome

Abstract

Aims/hypothesis: IGFs and their binding proteins are increasingly recognised as important in understanding the pathogenesis of cardiovascular disease. Low IGFBP-1, particularly coupled with low IGF‐I, is associated with increased cardiovascular risk. In relation to structural and regulatory parallels between IGFBP-1 and ‐ 2 we have now examined the hypothesis that IGFBP-2 may be a marker for cardiovascular risk. Methods: Fasting IGFBP-2, IGFBP-1, IGFBP-3, IGF‐I, IGF‐II, insulin, C-peptide, glucose, lipids, NEFAs, and HbA1c were measured in a cohort of 163 patients with type 2 diabetes. Individuals were categorised according to the presence or absence of the metabolic syndrome. Results: Patients with the metabolic syndrome had a lower IGFBP-2 concentration. Low circulating IGFBP-2 was associated with elevated fasting glucose (ρ = - 0.23, p = 0.003). IGFBP-2 correlated negatively with triglycerides (ρ = - 0.19, p = 0.01) and LDL-cholesterol (ρ = - 0.20, p = 0.01), and positively with insulin sensitivity (HOMA‐S) (ρ = 0.26, p = 0.02). Multivariate logistic regression demonstrated that low IGFBP-2 was independently associated with an increased risk of the metabolic syndrome (OR 0.31 [95 % CI 0.11 - 0.90]; p = 0.03). IGFBP-3 did not differ according to the presence or absence of metabolic syndrome. Conclusion/interpretation: Low IGFBP-2 is associated with multiple cardiovascular risk factors similarly to IGFBP-1. Such associations were not apparent for IGFBP-3. Lack of marked prandial regulation of IGFBP-2, in contradistinction to IGFBP-1, may make IGFBP-2 a more robust biomarker for identification of insulin-resistant individuals at high cardiovascular risk in epidemiological studies.

Key words

IGFBP - metabolic syndrome - type 2 diabetes - cardiovascular disease

References

• 1 Boni-Schnetzler M, Schmid C, Mary J L, Zimmerli B, Meier P J, Zapf J, Schwander J, Froesch E R. Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes.  Molecular Endocrinology. 1990;  4 1320-1326
• 2 Boulle N, Baudin E, Gicquel C, Logie A, Bertherat J, Penfornis A, Bertagna X, Luton J P, Schlumberger M, Le Bouc Y. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors.  European Journal of Endocrinology. 2001;  144 29-36
• 3 Clemmons D R. Role of peptide growth factors in development of macrovascular complications of diabetes.  Diabetes Care. 1991;  14 153-156
• 4 Clemmons D R, Snyder D K, Busby Jr W H. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects.  Journal of Clinical Endocrinology & Metabolism. 1991;  73 727-733
• 5 Cohen P, Peehl D M, Stamey T A, Wilson K F, Clemmons D R, Rosenfeld R G. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients.  Journal of Clinical Endocrinology & Metabolism. 1993;  76 1031-1035
• 6 Conover C A, Lee P D, Kanaley J A, Clarkson J T, Jensen M D. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans.  Journal of Clinical Endocrinology & Metabolism. 1992;  74 1355-1360
• 7 Cruickshank J K, Heald A H, Anderson S G, Cade J E, Sampayo J, Riste L K, Greenhalgh A, Taylor W, Fraser W, White A, Gibson J M. Epidemiology of the insulin-like growth factor system in three ethnic groups.  American Journal of Epidemiology. 2001;  154 504-513
• 8 De W, Czernichow P, Asfari M. Discordant regulation of insulin-like growth factor-II and insulin-like growth factor binding protein-2 gene expression in a rat beta-cell line.  Growth Regulation. 1996;  6 83-87
• 9 Ernst C W, White M E. Hormonal regulation of IGF-binding protein-2 expression in proliferating C2C12 myoblasts.  Journal of Endocrinology. 1996;  149 417-429
• 10 Expert Panel on Detection EaToHBCiA . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  Journal of the American Medical Association. 2001;  285 2486-2497
• 11 Gibson J M, Westwood M, Crosby Gordon S RC, Holly J M, Fraser W, Anderson C, White A, Young R J. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus.  Journal of Clinical Endocrinology & Metabolism. 1995;  80 1369-1375
• 12 Gibson J M, Westwood M, Young R J, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP‐1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM).  Journal of Clinical Endocrinology & Metabolism. 1996;  81 860-863
• 13 Goke B, Fehmann H C. Insulin and insulin-like growth factor-I: their role as risk factors in the development of diabetic cardiovascular disease.  Diabetes Research & Clinical Practice. 1996;  30 93-106
• 14 Heald A H, Cruickshank J K, Riste L K, Cade J E, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson J M. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP‐1) with glucose tolerance and cardiovascular risk in two populations.  Diabetologia. 2001;  44 333-339
• 15 Heald A H, Siddals K W, Fraser W, Taylor W, Kaushal K, Morris J, Young R J, White A, Gibson J M. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP‐1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.  Diabetes. 2002;  51 2629-2636
• 16 Janssen J A, Stolk R P, Pols H A, Grobbee D E, Lamberts S W. Serum total IGF‐I, free IGF‐I, and IGFBP‐1 levels in an elderly population: relation to cardiovascular risk factors and disease.  [erratum appears in Arterioscler Thromb Vasc Biol 1998 Jul; 18: 1197] Arterioscler Thromb Vasc Biol. 1998;  18 277-282
• 17 Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.  Circulation. 2002;  10 939-944
• 18 Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease.  Growth Hormone and IGF Research. 2003;  13 113-170
• 19 Kanety H, Kattan M, Goldberg I, Kopolovic J, Ravia J, Menczer J, Karasik A. Increased insulin-like growth factor binding protein-2 (IGFBP‐2) gene expression and protein production lead to high IGFBP‐2 content in malignant ovarian cyst fluid.  British Journal of Cancer. 1996;  73 1069-1073
• 20 Leinonen E S, Salonen J T, Salonen R M. et al . Reduced IGFBP‐1 is associated with thickening of the carotid wall in type 2 diabetes.  Diabetes Care. 2002;  25 1807-1812
• 21 Renehan A G, Jones J, Potten C S, Shalet S M, O'Dwyer S T. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.  British Journal of Cancer. 2000;  83 1344-1350
• 22 Renehan A G, Toogood A A, Ryder W D, Jones J, Potten C S, O'Dwyer S T, Shalet S M. Paradoxical elevations in serum IGF‐II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides.  Clinical Endocrinology. 2001;  55 469-475
• 23 Rudenski A S, Matthews D R, Levy J C, Turner R C. Understanding “insulin resistance”: both glucose resistance and insulin resistance are required to model human diabetes.  Metabolism Clinical & Experimental. 1991;  40 908-917
• 24 Sandhu M S, Heald A H, Gibson J M, Cruickshank J K, Dunger D B, Wareham N J. Circulating concentrations of insulin-like growth factor-I and the development of glucose intolerance: a prospective observational study.  Lancet. 2002;  359 1740-1745
• 25 Schmid C, Schlapfer I, Waldvogel M, Meier P J, Schwander J, Boni-Schnetzler M, Zapf J, Froesch E R. Differential regulation of insulin-like growth factor binding protein (IGFBP)-2 mRNA in liver and bone cells by insulin and retinoic acid in vitro.  FEBS Letters. 1992;  303 205-209
• 26 Schutt B S, Langkamp M, Rauschnabel U, Ranke M B, Elmlinger M W. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells.  J Mol Endocrinol. 2004;  32 859-868
• 27 Turner R C, Rudenski A S, Matthews D R, Levy J C, O'Rahilly S P, Hosker J P. Application of structured model of glucose-insulin relations to assess beta-cell function and insulin sensitivity.  Horm Metab Res Supplement. 1990;  24 66-71
• 28 Vaessen N, Heutink P, Janssen J A, Witteman J CM, Testers L, Hofman A, Lamberts S WJ, Oostra B A, Pols H AP, van Duijn C M. A polymorphism in the gene for IGF‐I: functional properties and risk for type 2 diabetes and myocardial infarction.  Diabetes. 2001;  50 637-642